Polycystic Ovary Syndrome: Definition and Management

Year 2024, Volume: 8 Issue: 2, 66 - 77, 15.12.2024

İlayda Koçak Kaan Küçükoğlu

Abstract

Polycystic ovary syndrome (PCOS) is a complex metabolic, endocrine disorder characterized by hyperandrogenism and menstrual abnormalities affecting 8.7%-17.8% of women of reproductive age. Although the etiology of PCOS is not known,environmental and genetic factors are thought to be factors in the emergence of this disease. Women with PCOS suffer from hair loss, hair growth, acne, facial fat, inflammation, irregular menstruation, darkening of the skin, headaches, infertility, depression, insulin resistance, infertility, obesity and polycystic ovaries. Lifestyle or diet, genetics, gut dysbiosis, environmental pollutants, neuroendocrine changes and obesity are among the risk factors that predispose women to PCOS. Although there is no definitive treatment for this disease, pharmacological and non-pharmacological methods are used to manage PCOS. Nonpharmacological treatment options include weight loss, improvement of sleep patterns, smoking cessation, exercise, psychological treatment, healthy nutrition, alternative medicine treatments, supplementary food and probiotic use. Oral contraceptives, antiandrogen drugs, drugs that increase insulin sensitivity, statins, medroxyprogesterone acetate, GLP-1 receptor agonists are pharmacological treatment options.

Keywords

Polycystic ovary syndrome, Complications, Insulin resistance, TreatmentNon-pharmacologic, Pharmacologic

References

• [1]March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod(2010) 25:544–51.
• [2]Berger JJ, Bates GW. Optimal management of subfertility in polycystic ovary syndrome. Int J Womens Health(2014) 6:613–21.
• [3]Gao Y, Liu H, Qiao L, et al. Study of Burden in Polycystic Ovary Syndrome at Global, Regional, and National Levels from 1990 to 2019. Healthcare(2023) 11:562.
• [4]Anala AD, Saifudeen ISH, Ibrahim M, Nanda M, Naaz N, Atkin SL. The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome. Journal of Clinical Medicine(2023) 12(14):4575. doi:10.3390/jcm12144575.
• [5]Ferreira SR M, A.B. Uterine function: From normal to polycystic ovarian syndrome Alterations. Curr Med Chem(2018) 25:1792–804.
• [6]Pathare ADS, Hinduja I, Mahadik RC. Basic aspects of endometrial receptivity in PCOS patients. Mol Biol Rep(2022) 49:1519–28.
• [7]Dapas M, Sisk R, Legro RS, Urbanek M, Dunaif A, Hayes MG. Family-based quantitative trait meta-analysis implicates rare noncoding variants in DENND1A in polycystic ovary syndrome. J Clin Endocrinol Metab(2019) 104:3835–50.
• [8]Singh S, Pal N,Shubham S, et al. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. J Clin Med(2023) 12:1454.
• [9]Norman RJ, Teede HJ. A new evidence-based guideline for assessment and management of polycystic ovary syndrome. Med J Aust(2018) 209:299–300.
• [10]Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod(2018) 33:1602–18.
• [11]Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine(2006) 30:19–26.
• [12]Azziz R, Carmina E, Dewailly D, et al. Androgen excess society. positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab(2006) 91:4237–45.
• [13]Lee TT, Rausch ME. Polycystic ovarian syndrome: Role of imaging in diagnosis. Radiographics(2020) 32:1643–57.
• [14]National Institutes of Health, Department of Health and Human Services 2013. Beyond Infertility: Polycystic Ovary Syndrome (PCOS). NIH Pub. No. 08-5863, Erişim tarihi, 27 Ocak 2024. Erişim adresi, www.nichd.nih. Gov/pkrisublications/pubs/upload/PCOS_booklet.pdf. 2008.
• [15]Osmanlıoğlu Ş, Omma T. Polikistik over sendromu fenotipleri ve metabolik disfonksiyon ilişkisi. İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi(2023) 11:1092–100.[16]Goodarzi MO, E C, R A. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol(2015) 145:213–25.
• [17]Ashraf S, M N, SUA R, F R, S A. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: A review. Egypt. J Med Hum Genet(2019) 20:25.
• [18]Kahn CR. The molecular mechanism of insulin action. Annu Rev Med(1985) 36:429–51.
• [19]Mishra P, Krishnan S, Rana S, Singh L, Sakinah M, Ab Wahid Z. Outlook of fermentative hydrogen production techniques: An overview of dark, photo and integrated dark-photo fermentative approach to biomass. Energy Strategy Reviews(2019) 24(July 2017):27–37. doi:10.1016/j.esr.2019.01.001.
• [20]Di Sarra D, Tosi F, Bonin C, et al. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. The Journal of clinical endocrinology and metabolism(2013) 98(6):2581–2588. doi:10.1210/jc.2013-1161.
• [21]Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod(2013) 28:777–84.
• [22]Cowan S, Lim S, Alycia C, et al. Lifestyle management in polycystic ovary syndrome -beyond diet and physical activity. BMC Endocr Disord(2023) 23:14.
• [23]Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: Purposes and pitfalls. Obs Gynecol Surv(2004) 59:141–54.
• [24]Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: ımplications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health(2019) 13:1179558119874042.
• [25]Mizgier M, Jarząbek-Bielecka G, Wendland N, et al. Relation between Inflammation, Oxidative Stress, and Macronutrient Intakes in Normal and Excessive Body Weight Adolescent Girls with Clinical Features of Polycystic Ovary Syndrome. Nutrients(2021) 13(3):896. doi:10.3390/nu13030896.
• [26]Liu Y, Liu H, Li Z, et al. The Release of Peripheral Immune Inflammatory Cytokines Promote an Inflammatory Cascade in PCOS Patients via Altering the Follicular Microenvironment. Front Immunol(2021) 12:685724.
• [27]Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and ınfertility: a new avenue for glp-1 receptor agonists. J Clin Endocrinol Metab(2020) 105:2695–709.
• [28]Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and metaanalysis. Fertility Sterility(2011) 95:1073–9.
• [29]Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab(2007) 18(7):280–5.
• [30]Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS):The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev(2016) 37:467–520.
• [31]Shorakae S, Ranasinha S, Abell S, et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clin Endocrinol(2018) 89:628–33.
• [32]Zuo T, Zhu M, Xu W. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. Oxidative Med Cell Longev(2016):1–14.
• [33]Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci(2019) 236:116940.
• [34]Li Y, Chen C, Ma Y, et al. Multi-system reproductive metabolic disorder: Significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS. Life Sci(2019) 228:167–75.
• [35]Liu Y, Yu Z, Zhao S, et al. Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality. J Assist Reprod Genet(2021) 38:471–7.
• [36]Mancini A, Bruno C, Vergani E, C, Giacchi E, Silvestrini A. Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights. Int J Mol Sci(2021) 22:1667.
• [37]Di Segni C, Silvestrini A, Fato R, et al. Plasmatic and Intracellular Markers of OxidativeStress in Normal Weight and Obese Patients with Polycystic Ovary Syndrome. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association(2017) 125(8):506–513. doi:10.1055/s-0043-111241.
• [38]EA GH, SA DP, ÓC VA, et al. Renoprotective and Hepatoprotective Effects Of Hippocratea Excelsa On Metabolic Syndrome In Fructose-Fed Rats. Farmacia(2020) 68:1106–19.
• [39]Li Y-J, Luo L-J, Harroun SG, et al. Synergistically dual-functional nano eye-drops for simultaneous anti-inflammatory and anti-oxidative treatment of dry eye disease. Nanoscale(2019) 11(12):5580–5594. doi:10.1039/C9NR00376B.
• [40]Özer A, Bakacak M, Kiran H, et al. Increased oxidative stress is associated with insulin resistance and infertility in polycystic ovary syndrome. Ginekol Pol(2016) 87:733–8.
• [41]Uyanikoglu H, Sabuncu T, Dursun H, Sezen H, Aksoy N. Circulating levels of apoptotic markers and oxidative stress parameters in women with polycystic ovary syndrome: A case-controlled descriptive study. Biomarkers(2017) 46:1–5.
• [42]Merkin SS, Phy JL, Sites CK, Yang D. Environmental determinants of polycystic ovary syndrome. Fertil Steril(2016) 106:16–24.
• [43]Rutkowska A, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril(2016) 106:948–58.
• [44]Ananthasubramanian P, Ananth S, Kumaraguru S, Barathi S, Santosh W, Vasantharekha R. Associated effects of endocrine disrupting chemicals (edcs) on neuroendocrine axes and neurotransmitter profile in polycystic ovarian syndrome condition. Proc Zool Soc(2021) 74:378–86.
• [45]Yang Q, Zhao Y, Qiu X, Zhang C, Li R, Qiao J. Association of serum levels of typical organic pollutants with polycystic ovary syndrome (PCOS): A case–control study. Hum Reprod(2015) 30:1964–73.
• [46]Urbanek M. The genetics of polycystic ovary syndrome. Natl Clin Pract Endocrinol Metab(2007) 3:103–11.
• [47]Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum Müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril(2002) 77:141–6.
• [48]Sterling E. Hormone levels and PCOS. Erişim tarihi(2015).
• [49]Shannon M, Wang Y. Polycystic ovary syndrome: A common but often unrecognized condition. J Midwifery Womens Health(2012) 57:221–30.
• [50]Marx TL, Mehta AE. Polycystic ovary syndrome: Pathogenesis and treatment over the short and long term. Cleve Clin J Med(2003) 70:31–45.
• [51]Strauss JF. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann NY Acad Sci(2003) 997:42–8.
• [52]Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond Engl(2010) 6:577–93.
• [53]Rosenfeld RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril(2012) 98:242–9.
• [54]Aşık BN, Ede Çintesun E. İleri glikasyon son ürünleri (AGE) ve polikistik over sendromu ilişkisi. İstanbul Sabahattin Zaim Üniversitesi Fen Bilimleri Enstitüsü Dergisi(2023) 5:8–17.
• [55]Tantalaki E, Piperi C, Livadas S, et al. Impact of dietary modificationof advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS. Hormones (Athens(2014) 13:65–73.
• [56]Dokras A. Does body weight affect cardiometabolic risk in women with polycystic ovary syndrome? Fertil Steril(2019) 111:56–7.
• [57]Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol(2019) 74:1376–414.,
• [58]Legro RS. Polycystic ovarian syndrome: Current and future treatment paradigms. Am J Obstet Gynecol(1998) 179:101–8.
• [59]Faghfoori Z, Fazelian S, Shadnoush M, Goodarzi R. Nutritional management in women with polycystic ovary syndrome: a review study. Diabetes Metab Syndr(2017) 11:429–32.
• [60]Zhang X, Zheng Y, Guo Y, Lai Z. The Effect of Low Carbohydrate Diet on Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials. Int J Endocrinol(2019):1–14.
• [61]Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modifcation in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab(1999) 84:1470–4.
• [62]Ujvari D, Hulchiy M, Calaby A, Nybacka Å, Byström B, Hirschberg AL. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of over weight/obese women with polycystic ovary syndrome. Hum Reprod(2014) 29:1526–35.
• [63]Soares NP, Santos AC, Costa EC, et al. Diet-Induced Weight Loss Reduces DNA Damage and Cardiometabolic Risk Factors in Overweight/Obese Women with Polycystic Ovary Syndrome. Ann Nutr Metab(2016) 68:220–7.
• [64]Oberg E, Gidlöf S, Jakson I, Mitsell M, Tollet Egnell P, Hirschberg AL. Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modifcation intervention-A randomized controlled trial. Clin Endocrinol(2019) 90:468–78.
• [65]Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in repro ductive outcome for all forms of fertility treatment. Hum Reprod(1998) 13:1502–5.
• [66]Crosignani PG, ColomboM, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod(2003) 18:1928–32.
• [67]Tolino A, Gambardella V, Caccavale C, et al. Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol(2005) 119:87–93.
• [68]Kuchenbecker WK, Groen H, Asselt SJ, et al. In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation. Hum Reprod(2011) 26:2505–12.
• [69]Lass N, Kleber M, Winkel K, Wunsch R, Reinehr T. Efect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab(2011) 96:3533–40.
• [70]Ornstein RM, Copperman NM, Jacobson MS. Efect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol(2011) 24:161–5.[71]Marzouk TM, Sayed Ahmed WA. Efect of Dietary Weight Loss on Men strual Regularity in Obese Young Adult Women with Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol(2015) 28:457–61.
• [72]Zeind CS, Carvalho MG. Applied Therapeutics: The Clinical Use of Drugs. Eleventh. Philadelphia Wolters Kluwer Health; (2017).
• [73]Sam S, Ehrmann DA. Pathogenesis and Consequences of Disordered Sleep in PCOS. Clinical Medicine Insights: Reproductive Health(2015) 13. doi:10.1177/1179558119871269.
• [74]Tao Y, Liu B, Chen Y, et al. Genetically Predicted Cigarette Smoking in Relation to Risk of Polycystic Ovary Syndrome. Clin Epidemiol(2021) 13:527–32.
• [75]Waylen A, Metwally M, Jones G, Wilkinson A, Ledger W. Efects of cigarette smoking upon clinical outcomes of assisted reproduction: a meta-analysis. Hum Reprod Update(2009) 15:31–44.
• [76]Legro RS, Chen G,Kunselman AR, et al. Reproductive Medicine Network. Smoking in infertile women with polycystic ovary syndrome: baseline validation of self-report and effects on phenotype. Hum Reprod(2014) 29:2680–6.44.
• [77]Raja-Khan N, Agito K, Shah J, et al. Mindfulness-based stress reduction for overweight/obese women with and without polycystic ovary syndrome: design and methods of a pilot randomized controlled trial. Contemp Clin Trials(2015) 41:287–97.
• [78]Stefanaki C, Bacopoulou F, Livadas S, et al. Impact of a mindfulness stress management program on stress, anxiety, depression and quality of life in women with polycystic ovary syndrome: a randomized controlled trial. Stress(2015) 18:57–66.
• [79]Abdollahi L, Mirghafourvand M, Babapour JK, Mohammadi M. Efective ness of cognitive-behavioral therapy (CBT) in improving the quality of life and psychological fatigue in women with polycystic ovarian syndrome. J Psychosom Obstet Gynecol(2019) 40:283–93.
• [80]Ludwig DS, Kabat-Zinn J. Mindfulness in medicine. Jama(2008) 300:1350–2.
• [81]Hâkimi O, Cameron LC. Effect of Exercise on Ovulation: A Systematic Review. Sports Med(2016) 47:1555–67.
• [82]Kite C, Lahart IM, Afzal I, et al. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Syst Rev(2019) 8:51.
• [83]Szczuko M, Sankowska P, Zapałowska-Chwyć M, Wysokiński P. Studies on the quality nutrition in women with polycystic ovary syndrome (PCOS. Rocz Panstw Zakl Hig(2017) 68:61–7.
• [84]Kim CH, Chon SJ, Lee SH. Efects of lifestyle modifcation in polycystic ovary syndrome compared to metformin only or metformin addition: a systematic review and meta-analysis. Sci Rep(2020) 10:7802.
• [85]Atiomo W, Read A, Golding M, et al. Local recruitment experience in a studycomparing the effectiveness of a low glycaemic index diet with a low calorie healthy eating approach at achieving weight loss and reducing the risk of endometrial cancer in women with polycystic ovary syndrome (PCOS. Contemp Clin Trials(2009) 30:451–6.
• [86]Katcher HI, Kunselman AR, Dmitrovic R, et al. Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome. Fertil Steril(2009) 91:1175–82.
• [87]Marsh KA, Steinbeck KS, Atkinson FS, Petocz P, Brand-Miller JC. Efect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am J Clin Nutr(2010) 92:83–92.
• [88]Mcbreairty LE, Chilibeck PD, Gordon JJ, Chizen DR, Zello GA. Polycystic ovary syndrome is a risk factor for sarcopenic obesity: a case control study. BMC Endocr Disord(2019) 19:70.
• [89]Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutri ents and hormones in polycystic ovary syndrome. Am J Clin Nutr(2007) 85:688–94.
• [90]Leri M, Scuto M, Ontario ML, et al. Healthy effects of plant polyphenols: molecular mechanisms. Int J Mol Sci(2020) 21:1250.
• [91]Mirabelli M, Chiefari E, Arcidiacono B, et al. Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases. Nutrients(2020) 12:1066.
• [92]Li Y, Peng C, Cao G, Li W, Hou L. Tai chi for overweight/obese adolescent and youngwomen with polycystic ovary syndrome: Study protocol for a randomized controlled trial. Trials(2018) 19:512.
• [93]Li Y, Zheng Q, Sun D, et al. Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome. J Cell Physiol(2018) 234:7435–47.
• [94]Raja-Khan N, Stener-Victorin E, Wu X, Legro RS. The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am J Physiol Metab(2011) 301:1–10.
• [95]Jia LY, Feng JX, Li JL, et al. The Complementary and Alternative Medicine for Polycystic Ovary Syndrome: A Review of Clinical Application and Mechanism. Evid.-Based Complement. Altern Med(2021):1–12.
• [96]Mohseni M, Eghbali M, Bahrami H, Dastaran F, Amini L. Yoga Effects on Anthropometric Indices and Polycystic Ovary Syndrome Symptoms in Women Undergoing Infertility Treatment: A Randomized Controlled Clinical Trial. Evid Based Complement Altern Med(2021):1–9.
• [97]Shirvani-Rad S, Tabatabaei-Malazy O, Mohseni S, et al. Probiotics as a Complementary Therapy for Management of Obesity: A Systematic Review. Evid-Based Complement Altern Med; (2021).
• [98]Zhang Y, Guo X, Ma S, et al. The Treatment with Complementary and Alternative Traditional Chinese Medicine for Menstrual Disorders with Polycystic Ovary Syndrome. Evid.-Based Complement. Altern Med(2021):1–19.
• [99]Thomson RL, Spedding S, Brinkworth GD, Noakes M, Buckley JD. Seasonal effects on vitamin D status influence outcomes of lifestyle intervention in overweight and obese women with polycystic ovary syndrome. Fertil Steril(2013) 99:1779–85.
• [100]Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev(2012) 13:1122.
• [101]Lee R, Joy Mathew C, Jose MT, Elshaikh AO, Shah L, Cancarevic I. A Review of the Impact of Bariatric Surgery in Women With Polycystic Ovary Syndrome. Cureus(2020) 12:10811.
• [102]Lindheim L, Bashir M, Münzker J, et al. Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study. PLoS One(2017) 12:168390.
• [103]Torres PJ, Siakowska M, Banaszewska B, et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab(2018) 103:1502–1.
• [104]Bhalla P, Rengaswamy R, Karunagaran D, Suraishkumar G, Sahoo S. Metabolic modeling of host–microbe interactions for therapeutics in colorectal cancer. NPJ Syst Biol Applicat(2022) 8:1.
• [105]Ahmadi S, Jamilian M, Karamali M, et al. Probiotic supplementation and the efects on weight loss, glycaemia and lipid profles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil(2017) 20:254–61.
• [106]Guarner F, Khan AG, Garisch J, et al. World Gastroenterology Organisation Global Guidelines. Journal of Clinical Gastroenterology(2012) 46(6):468–481. doi:10.1097/MCG.0b013e3182549092.
• [107]Fernandes R, Rosario VA, Mocellin MC, Kuntz MG, Trindade EB. Efects of inulin-type fructans, galactooligosaccharides and related synbiotics on infammatory markers in adult patients with overweight or obesity: a systematic review. Clin Nutr(2017) 36:1197–206.
• [108]Gholizadeh Shamasbi S, Dehgan P, Mohammad-Alizadeh Charandabi S, Aliasgarzadeh A, Mirghafourvand M. The effect of resistant dextrin as a prebiotic on metabolic parameters and androgen level in women with polycystic ovarian syndrome: a randomized, triple-blind, controlled, clinical trial. European journal of nutrition(2019) 58(2):629–640. doi:10.1007/s00394-018-1648-7.
• [109]Cozzolino M, Vitagliano A, Pellegrini L, et al. Therapy with probiotics and synbiotics for polycystic ovarian syndrome: a systematic review and meta-analysis. Eur J Nutr(2022) 59:2841–56.
• [110]Grimes DA, Economy KE. Primary prevention of gynecologic cancers. Am J Obstet Gynecol(1995) 172:227–35.
• [111]Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline. J Clin Endocrinol Metab(2008) 93:1105–20.
• [112]Rotterdam. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).Human Reproduction(2004) 19(1):41–47. doi:10.1093/humrep/deh098.
• [113]Nair S. Hirsutism and acne in polycystic ovary syndrome. 1th ed. (Eds MR, GN A, R A, eds). Kent, U.K Anshan Ltd; (2007).
• [114]Zimmerman Y, Eijkemans M, Coelingh Bennink H, Blankenstein M, Fauser B. The effect of combined oral contraception on testosterone levels in healthy women: A systematic review and meta-analysis. Hum Reprod(2014) 20:76–105.
• [115]V L, D L, D D ’Anton., A M, G M. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab(1998) 83:99–102.
• [116]Venturoli S, Marescalchi O, Colombo F, et al. Prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab(1999) 84:1304–10.
• [117]Paradisi R, Fabbri R, Battaglia C, Venturoli S. Ovulatory effects of flutamide in the polycystic ovary syndrome. Gynecol Endocrinol(2013) 29:391–5.
• [118]Calaf J, López E, Millet A, et al. Spanish Working Group for Hirsutism. J Clin Endocrinol Metab(2007) 92:3446–52.
• [119]Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab(2000) 85:89–94.
• [120]Ibáñez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Human Reproduction Update(2006) 12(3):243–252. doi:10.1093/humupd/dmi054.
• [121]Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health(2011) 3:25–35.
• [122]Lakryc E, Motta E, Soares J, Haidar MA, Lima G, Baracat E. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol(2003) 17:57–63.
• [123]Tartagni M V, Alrasheed H, Damiani GR, et al. Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: A pilot study. J Pediatr Adolesc Gynecol(2014) 27:161–5.
• [124]Rittmaster RS. Antiandrogen treatment of polycystic ovary syndrome. Endocrinol Metab Clin North Am(1999) 28:409–21.[
• 125]Pasquali R,Gambineri A. Therapy of endocrine disease: Treatment of hirsutism in the polycystic ovary syndrome. Eur J Endocrinol(2014) 170:75–90.
• [126]Abdalla M, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol MetabAbdalla, M., Deshmukh, H., Atkin, S. & Sathyapalan, T. (n.d.). A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab, 11, 2042018820938305.(2020) 11:2042018820938305.
• [127]Geller DH, Pacaud D, Gordon CM, Misra M. Of the Drug and Therapeutics Committee of the Pediatric Endocrine Society. Emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycysticovary syndrome (PCOS. Int J Pediatr Endocrinol(2011):9.
• [128]Dasari P, Pranahita GK. The efficacy of metformin and clomiphene citrate combination compared with clomiphene citrate alone for ovulation induction in infertile patients with PCOS. J Hum Reprod Sci(2009) 2:18–22.
• [129]Sahra IB, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene(2008) 27:3576–86.
• [130]Salpeter SR B, NS K, JA S, E.E. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med(2008) 121:149–57.
• [131]Lashen H. Role of metformin in the management of polycystic ovary syndrome. Therapeutic Adv Endocrinol Metabol(2010) 1:117–28.
• [132]Aroda VR, Edelstein SL, Goldberg RB, et al. Diabetes prevention program research group. long-term metformin use and vitamin b12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab(2016) 101:1754–61.
• [133]Zhao J, Ma M, Zeng Z, Yu P, Gong D, Deng S. Production, purification and biochemical characterisation of a novel lipase from a newly identified lipolytic bacterium Staphylococcus caprae NCU S6. Journal of Enzyme Inhibition and Medicinal Chemistry(2021) 36(1):249–257. doi:10.1080/14756366.2020.1861607.
• [134]Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med(1999) 16:179–92.
• [135]Cataldo NA, Abbasi F, Mclaughlin TL, Lamendola C, Reaven GM. Nov 1. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril(2001) 76:1057–59.
• [136]Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy25:244–52.
• [137]Froment P, Touraine P. Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS. PPAR Res(2006):73986.
• [138]Brettenthaler N, Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab(2004) 89:3835–840.
• [139]GroupTESHRE /A. SRM-SPCOSCW. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod(2008) 23:462–77.
• [140]Christin-Maitre S, Hugues JN. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod(2003) 18:1626–31.
• [141]Clomid. prescribing information. Bridgewater, N.J.: Sanofi-Aventis U.S, Erişim tarihi, 27 Aralık 2023. Erişim adresi, http://products.sanofi.us/ clomid/clomid.html. Accessed March 27,. (2013).
• [142]UA N, A E, MR G. Polycystic Ovary Syndrome A Review of Treatment Options With a Focus on Pharmacological Approache. P & T : a Peer-reviewed Journal for Formulary Management(2013) 38:336–55.
• [143]Borenstein R, Schwartz ZS, Yemini M, Barash A, Fienstein M, Rozenman D. Tamoxifen treatment in women with failure of clomiphene citrate therapy. Aust N Z J Obstet Gynaecol(1989) 29:173–75.
• [144]Dhaliwal LK, Suri V, Gupta KR, Sahdev S. Tamoxifen: An alternative to clomiphene in women with polycystic ovarysyndrome. J Hum Reprod Sci(2020) 4:76.
• [145]Casper RF, Mitwally MF. Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clin Obstet Gynecol(2011) 54:685–95.
• [146]Gysler M, March CM, Mishell DR, Bailey EJ. A decade’s experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertility and Sterility(1982) 37(2):161–167. doi:10.1016/S0015-0282(16)46033-4.
• [147]Al-Omari WR, Sulaiman WR, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynecol Obstetrics(2004) 85:289–91.
• [148]Carroll N, Palmer JR. A comparison of intrauterine versus intracervical insemination in fertile single women. Fertil Steril(2001) 75:656–60.
• [149]Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics(2015) 70:765–9.
• [150]Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rational, results, reflections refinements. Hum Reprod Update(1999) 5:493–9.
• [151]Veltman-Verhulst SM, Cohlen BJ, Hughes E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. In: Veltman-Verhulst SM, ed. Cochrane Database of Systematic Reviews. Chichester, UK John Wiley & Sons, Ltd (2012).
• [152]Kodaman PH, Duleba AJ. Statins in the treatment of polycystic ovary syndrome. Semin Reprod Med(2008) 26:127–38.
• [153]Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca–interstitial cell proliferation and steroidogenesis. Fertil Steril(2004) 82:1193–7.
• [154]Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with polycystic ovary syndrome: A meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes(2012) 120:357–75.
• [155]Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab(2009) 94:4938–45.
• [156]Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS. Clin Endocrinol(2010) 72:566–8.
• [157]Sathyapalan T, Hobkirk JP, Javed Z, et al. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory- protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Front Endocrinol(2019) 10:394.
• [158]Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled study. J Clin Endocrinol Metab(2009) 94:103–8.
• [159]Sathyapalan T, Smith KA, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: Randomized controlled study. Ann Clin Biochem(2012) 49:80–5.
• [160]Sathyapalan T, Shepherd J, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab(2012) 97:3951–5.
• [161]Chen LL, Zheng JH. Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: A systematic review and meta-analysis. Medicine(2021) 100:26289.
• [162]Haydardedeoglu B, Simsek E, Kilicdag EB, Bagis T. Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. Int J Gynaecol Obstet(2009) 105:32–5.
• [163]Bagis T, Gokcel A, Zeyneloglu HB, Tarim E, Kilicdag EB, Haydardedeoglu B. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocrinol Metab(2002) 87:4536–40.
• [164]Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet(2008) 103:44–9.
• [165]Dalla Man C, F M, A S, RA R, A V, CA C. Model of GLP-1 action on insulin secretion in nondiabetic subjects. Am J Physiol Endocrinol Metab(2010) 298:1115–21.
• [166]Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: A critical review of the evidence. Obes Sci Prac(2017) 3:3–14.
• [167]Bloemendaal L., Ten Kulve J, Fleur S, Ijzerman R, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS. J Endocrinol(2014) 221:1–16.
• [168]Yaribeygi H, Sathyapalan T, Sahebkar AJ. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci(2019) 234:116776.
• [169]Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online(2019) 39:332–42.
• [170]Luo Y, Cui C, Han X, Wang Q, Zhang C. The role of miRNAs in polycystic ovary syndrome with insulin resistance. J Assist Reprod Genet(2021) 38:289–304.[
• 171]Long W, Zhao C, Ji C, et al. Characterization of serum microRNAs profile of PCOS and identification of novel non-invasive biomarkers. Int J Exp Cell Physiol Biochem Pharmacol(2014) 33:1304–15.
• [172]Wu HL, Heneidi S, Chuang TY, et al. The expression of the miR-25/93/106b family of micro-RNAs in the adipose tissue of women with polycystic ovary syndrome. J Clin Endocrinol Metab(2014) 99:2754–2761.
• [173]Xu B, Zhang YW, Tong XH, Liu YS. Characterization of microRNA profile in human cumulus granulosa cells: Identification of microRNAs that regulate Notch signaling and are associated with PCOS. Mol Cell Endocrinol(2015) 404:26–36.
• [174]Naji M, Aleyasin A, Nekoonam S, Arefian E, Mahdian R, Amidi F. Differential expression of miR-93 and miR-21 in granulosa cells and follicular fluid of polycystic ovary syndrome associating with different phenotypes. Sci Rep(2017) 7:14671.
• [175]QiX, Yun C, Sun L, et al. Gut microbiota–bile acid–interleukin-22 axis orchestrates polycystic ovary syndrome. J Endocrinol(2019) 25:1225–33.